The FDA has approved sotatercept-csrk (Winrevair – Merck), a first-in-class activin signaling inhibitor, to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events in adults with WHO Group 1 pulmonary arterial hypertension (PAH).
STANDARD TREATMENT — Drugs that are FDA-approved for treatment of PAH are listed in Table 3. Use of these drugs alone or in combination has been shown to improve exercise capacity and reduce the risk of clinical worsening events in patients with PAH.
- Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
- A New Indication for Semaglutide (Wegovy)
- Intravenous Acetaminophen/Ibuprofen (Combogesic IV)
- iDose TR — A Travoprost Implant for Glaucoma
- Antibiotic Prophylaxis for Dental Procedures
- Tepotinib (Tepmetko) for NSCLC (online only)
- Belzutifan (Welireg) for Advanced Renal Cell Carcinoma (online only)
- Lifileucel (Amtagvi): A Cellular Therapy for Melanoma (online only)
ISSUE
The oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid was approved by the FDA in 2020 for use alone (Nexletol – Esperion) and in a fixed-dose combination with the cholesterol absorption inhibitor ezetimibe (Nexlizet) as an adjunct to maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-cholesterol (LDL-C) lowering. The indication has now been expanded to include reducing the risk of myocardial infarction (MI) and coronary revascularization in adults with established cardiovascular disease (CVD) or at high risk for a CVD event who are unable to take recommended statin therapy.1-3
STANDARD TREATMENT — HMG-CoA reductase inhibitors (statins) are the drugs of choice for most …